Study finds automated breast ultrasound is an effective alternative to handheld ultrasound for breast cancer screening
Peer-Reviewed Publication
This month, we're turning our attention to Breast Cancer Awareness Month, a time dedicated to increasing awareness, supporting early detection, and highlighting the ongoing research shaping the future of breast cancer treatment and prevention.
Updates every hour. Last Updated: 19-Oct-2026 21:16 ET (20-Oct-2026 01:16 GMT/UTC)
Results from ECOG-ACRIN’s CompassHER2-pCR trial identify clinical and molecular predictors of pathologic complete response (pCR) after 12 weeks of THP, a less intensive neoadjuvant regimen combining one chemotherapy drug with two HER2-targeted drugs. It is the largest prospective trial of this approach in stage II-IIIA HER2+ breast cancer. Follow-up is ongoing to assess 3-year recurrence-free survival among patients who had a pCR. Published in JCO, the findings will be featured in a podcast.